News

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...
The U.S. Food and Drug Administration has granted full approval for Moderna's MRNA.O COVID-19 vaccine, Spikevax, in children ...
Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug ...
Much of the public distrust stems from false information around messenger RNA (mRNA) vaccines for COVID-19, even though they ...
TAMPA — Florida’s top health official blasted the manufacturer’s of mRNA COVID-19 vaccines and wants the federal government to do more to help those he described as the “vaccine injured.” Florida ...
Moderna (MRNA) stock in focus as the company cancels plans for an mRNA manufacturing plant in Japan amid a challenging ...
The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.
Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which could set the stage for the company’s combination COVID-19/influenza shot.
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added ...
Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...
Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 ...
Moderna Japan had planned to build an mRNA drug plant at Shonan Health Innovation Park in Kanagawa prefecture. The company shelved the plan, citing weak demand for vaccines and a poor business ...